Osteoglycin (OGN) has been noted for its implication in cardiovascular disease in recent studies. However, the relationship between OGN and angiogenesis remains unknown. Therefore, we aimed to investigate the effect of OGN on ischaemia-induced angiogenesis and to address the underlying mechanisms. 
Introduction
Angiogenesis, the formation of new capillaries from pre-existing vessels, can be triggered under conditions of ischaemia, hypoxia, or tumour metastasis. 1 It is an adaptive response and a well-controlled process regulated by numerous environmental factors. Angiogenesis is often implicated in cardiovascular diseases, including peripheral artery disease (PAD), 2 coronary artery disease, 3 thoracic aortic aneurysm, 4 and diseases where ischaemia takes place. 5 Although angiogenesis has been anticipated as a therapeutic target for ischaemic diseases, the regulatory mechanism has not been clearly elucidated. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) signalling pathway activation is crucial for inducing therapeutic angiogenesis and has been used to treat ischaemic disease. [6] [7] [8] However, the safety and efficiency of VEGF treatment are still under debate. In addition to the VEGF-VEGFR2 signalling pathway, constituents of the extracellular matrix (ECM), including collagen, gelatin, and proteoglycans, are also involved in angiogenesis. 9, 10 Consequently, an association between growth factor receptors and the ECM has been implicated in the regulation of angiogenesis. 9 Different mechanisms have been found involved in the interaction of VEGFR2 and ECM components, and the ECM seems to be a new target for modulating angiogenesis. Osteoglycin (OGN) is a proteoglycan in the ECM. It is expressed in a variety of organs and exerts actions in bone formation, 11 collagen fibrillogenesis, 12 and tumours, 13 and it is also implicated in connective tissue diseases. 14 In 2008, OGN was first found to be correlated with left ventricular mass, 15 which led to the emergence of studies exploring the role of OGN in cardiovascular diseases. These studies revealed that OGN had protective effects against cardiac ageing 16 and heart failure following myocardial infarction. 17 However, whether OGN participates in angiogenesis and how it functions as a proteoglycan is still unknown. One purpose of this study is to clarify whether OGN participates in ischaemia-induced angiogenesis. The expression of OGN was detected, and OGN knockout (KO) mice were used to establish a limb ischaemia mouse model. Another purpose of this study is to investigate how OGN is involved in angiogenesis and to determine the relationship of OGN with VEGF-VEGFR2 signalling.
Methods
An expanded methods section with details of reagents and ethical issues are provided as a Supplementary material online.
Animas model and assessments
OGN KO mice and their wild-type (WT) littermates used in the present study were provided by Professor Song Huai-Dong. All the procedures were approved by the Animal Care Committee of Shanghai Jiaotong University and in compliance with the animal management rules of the Chinese Ministry of Health and NIH guidelines. Mice were anesthetized and subjected to ischaemia of the right hind-limb by right femoral vessel (artery and vein) ligation. Ischaemia and reperfusion of the hind-limb were evaluated by serial laser Doppler imaging and angiogenesis in tissue sections of the gastrocnemius muscle.
For VEGFR2 inhibition, a VEGFR2 kinase inhibitor (Millipore 676485) was dissolved in ethanol and stored at 4 C. A dosage of 1 mg/kg in 100 mL ethanol was carefully and slowly injected into the skeletal muscle of mice on the day before surgery, 3 days after surgery, 7 days after surgery, and 11 days after surgery. For the control animals, only ethanol was injected. Mice were anesthetized by isoflurane inhalation during the procedure. On the 14th day after surgery, perfusion was assessed, and samples of skeletal muscle were collected for immunofluorescence staining.
Immunofluorescence and immunohistochemistry
Immunofluorescence and immunohistochemistry were performed according to a previously established protocol. Heat-mediated antigen retrieval was used to enhance antigen exposure before detection. Antibodies against OGN and CD31 were obtained from Santa Cruz (sc-374463 and sc-1506, respectively) and CD45 antibody was obtained from Abcam (ab10558). 
Western blot

RNA extraction and real-time PCR
Total RNA was isolated according to the standard protocol. Reverse transcription was performed using the Promega Reverse transcription system. Real-time (RT) PCR was performed using Takara SYBR Green Reagents. The primer sequences are listed in the Supplementary material online.
Cell culture and RNA interference
Human umbilical vein endothelial cells (HUVECs) were used for cell experiments. Primary cells were isolated from fresh umbilical cords, which were donated by six different parturients. All the procedures were approved by the Ethics Committee of Ruijin Hospital and conformed to the declaration of Helsinki. Cords without either damage or infection were used. After cutting both ends of the cord, a cannula at was introduced into each extremity of the vein and tightly maintained with string. A solution of 0.9% saline was used to wash the cord vein until the effluent buffer was slightly pink. HUVECs were isolated by 2.5% collagenase (Sigma) and subsequently cultured in endothelial cell (EC) medium and ECGS supplements obtained from ScienCell. Small interfering RNA (siRNA) was transfected using Lipofectamine. Cells were cultured in serum-free OPTI-MEM medium for approximately 6 h. Then, siRNA was mixed with Lipofectamine and added to the cells with fresh OPTI-MEM. After 6 h, the OPTI-MEM containing siRNA and Lipofectamine was replaced with complete medium with 5% FBS. The negative control (NC) (sc-37007) and OGN (sc-61267) siRNAs were used at a concentration of 50 nM.
Plasmid construction and transfection
Human OGN cDNA was chemically synthesized. The cDNA fragments were cloned into the pcDNA3.1 plasmid. Constructs were verified by sequencing. Transient transfection of HUVECs with either control pcDNA3.1 or pcDNA3.1-OGN plasmids were conducted using Lipofectamine reagent (Invitrogen).
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In vitro tube formation, proliferation, and migration assays HUVECs were transfected with siRNA for 48 h and then seeded into 96-well plates on Matrigel (BD: 356234). Tube formation was observed every hour after cell seeding. Representative photos were taken 4 h after seeding, and randomly selected microscopic fields were selected for quantity. Tube length was calculated by using Image-Pro Plus software. The proliferation rates of HUVECs after siRNA interference were measured by EdU staining (RiboBio C10310-3). Transfected cells were starved without serum for 12 h, after which the medium was replenished with FBS and EdU staining was observed Osteoglycin and ischemia-induced angiogenesis 6 h later. Migration was estimated by the wound healing assay. The scrape was made after cell contact inhibition.
Estimations of cell functions were performed using HUVECs at passages 3-5, and the results were repeated in cells from at least four different individuals.
Aortic ring assay
Aortic rings were dissected from the descending aorta of 8-week-old male mice. Euthanasia was performed using a combination of isoflurane inhalation and intra-peritoneal injection of pentobarbital sodium, and then the thorax was opened along the lower costal border and diaphragm to access the heart, which was dissected. All the procedures were approved by the Animal Care Committee of Shanghai Jiaotong University and in compliance with the animal management rules of the Chinese Ministry of Health and the NIH guidelines. Mice aortic rings were embedded on a collagen gel (collagen type I, BD Biosciences) after serum starvation overnight. MCDB-131 (Gibco) with 2.5% FBS (Gibco) and 30 ng/mL VEGF (PeproTech) supplements was used as the medium. Photographs were taken on the 7th day after aortic ring explanation, and quantitative results were recorded as sprouting numbers by Image Pro Plus. The method of aortic ring transfection is presented in the Supplementary material online.
Immunoprecipitation
Fresh lysates from either cells or mice hindlimb tissue were used in the procedure. Control Agarose Resin was used to pre-clear the lysate. Co-immunoprecipitation (IP) was performed according to the user guide of the Pierce Crosslink IP Kit (Thermo Scientific 26147). In short, 20 mg pf antibody for IP or IgG was incubated with Protein A/G Plus Agarose on a rotator at room temperature for 60 min and then cross-linked. The antibody-agarose complex was incubated with pre-cleared lysate (containing antigen) at 4 C overnight. Then, the antigen was eluted, and the samples obtained from co-IP were used for western blot analysis.
Statistical analysis
Data are presented as the mean 6 SD. The Shapiro-Wilk test was used for normality. For normal or approximately normal variables, Student's t-test (for two group comparisons) or analysis of variance (three or more groups) was used. Detailed information about the statistical analysis is listed in the figure legend. Statistical significance was defined at a P-value of <0.05.
Results
Expression of OGN was decreased in the mouse limb ischaemia model
OGN expression was detected in mouse limbs at different time points after ischaemia. The expression of OGN gradually decreased with time after ischaemia and maintained its decline after then ( Figure  1A) . Quantitative results of the western blot are presented in Figure  1B . To determine whether the decrease of OGN protein levels resulted from a reduction of mRNA, we performed RT-PCR. As shown in Figure 1C , relative mRNA levels of OGN were also gradually reduced over time similar to the change of OGN protein levels. Furthermore, immunostaining showed that OGN was found in mouse limbs where CD31-positive ECs were also present. However, in mouse ischaemic limbs, although more CD31-positive cells infiltrated, the expression of OGN was dramatically down-regulated ( Figure 1D ). Taken together, these results suggested that the OGN expression was decreased early after onset of ischaemia and was maintained at this lower level after reperfusion.
OGN deficiency promoted blood flow recovery after ischaemia in vivo and aortic ring angiogenesis ex vivo
To explore the role of OGN in ischaemia-induced angiogenesis, OGN KO mice were used. The baseline blood flow, vasculature, and ECM of OGN KO mouse did not differ from WT control mice (Supplementary material online, Figure 1 ). In our mouse model of limb ischaemia, we found that the KO group had a much faster blood flow recovery than the WT group ( Figure 2A) . The blood flow recovery of WT mice was 24. 8 6 5.4%, 44.6 6 9.4%, and 63.5 6 15.7% at Day 4, Day 7, and Day 14 after limb ischaemia, respectively, while that of the KO mice was 46.5 6 6.9%, 71.5 6 17.0%, and 83.0 6 9.2%, respectively ( Figure 2B) . Histology, angiogenesis, inflammatory cell infiltration and the levels of inflammatory cytokines were analysed seven days after ischaemia. The data showed that the capillary densities measured by CD31-positive cells in the gastrocnemius were significantly higher in KO mice compared with WT mice ( Figure 2C ). However, no difference was observed in the histology, inflammatory cell infiltration and levels of inflammatory cytokines between these two groups (Supplementary material online, Figure 2 ).
To evaluate the contribution of OGN in vascular cells, the ex vivo aortic ring sprouting assay was performed. We found that aortic rings from KO mice had stronger angiogenic growth than aortic rings from WT mice as quantified by the sprouting numbers ( Figure 2D ). In addition, we examined corneal angiogenesis and found that alkali-induced corneal neovascularization as measured by CD31-positive cells was more robust in KO mice than WT mice (Supplementary material online, Figure 3) .
We further evaluated the effect of gain-of-OGN function on angiogenesis. First, we examined cornea vessels in mice with the systemic delivery of an OGN-expressing adenovirus. Overexpression of OGN revealed a much smaller number of vessels in the cornea 10 days after alkali injury (Supplementary material online, Figure 4A ). Secondly, aortic sprouting was attenuated in aortic rings treated with OGN adenovirus ex vivo. Thirdly, recombinant OGN also inhibited aortic sprouting of aortic rings (Supplementary material online, Figure 4B and C). These data together indicate that OGN deficiency enhanced angiogenesis while OGN overexpression inhibited angiogenesis.
OGN negatively regulated EC tube formation, proliferation, and migration in vitro
Because ECs play critical roles in angiogenesis, we determined the role of OGN in tube formation, proliferation, and migration, all of which are important events in the angiogenic process. We used primary cultured HUVECs, in which we detected significant expression levels of OGN (Supplementary material online, Table 1 ). Knockdown of OGN with siRNA increased tube formation in Matrigel ( Figure 3A and Supplementary material online, Figure 5) . Additionally, HUVEC proliferation as measured by the 5-ethynyl-2 0 -deoxyuridine (EdU) cell proliferation assay was increased ( Figure 3B ). In addition, HUVECs treated with OGN siRNA displayed an increased capacity of migrating in the woundhealing assay ( Figure 3C) . Moreover, the EC functions of tube formation, proliferation, and migration were also assessed in HUVECs transfected with a plasmid overexpressing OGN. The data showed that tube formation was inhibited in cells overexpressing OGN ( Figure 3D) , and fewer EdU-positive cells were detected in cells overexpressing OGN ( Figure . . 
3E).
Migration speed in the wound healing assay was impeded when OGN was increased ( Figure 3F) . Thus, these data indicate that altering OGN expression influenced the tube formation, proliferation, and migration of ECs, which are essential for angiogenesis.
OGN regulated the VEGF-VEGFR2 signalling pathway
Because VEGF-VEGFR2 is critical in angiogenesis, we examined whether OGN affects the VEGF-VEGFR2 pathway. We first detected the expression of VEGF and VEGFR2 levels and found that OGN knockdown did not alter either VEGF or VEGFR2 protein levels (Supplementary ma terial online, Figure 5E ). Next, we examined whether activation of the VEGF signalling pathway was modulated by OGN suppression. Upon VEGF stimulation, phosphorylation of VEGFR2 was observed at 5 min and declined after 15 min in HUVECs treated with NC siRNA. However, HUVECs transfected with OGN siRNA revealed stronger and longer instances of VEGFR2 phosphorylation. Similarly, AKT and ERK1/2 activation in response to VEGF was also enhanced and lasted longer in OGN-knockdown HUVECs ( Figure 4A ). On the other hand, overexpression of OGN suppressed the activation of VEGF-stimulated VEGFR2, AKT, and ERK ( Figure 4B) . The quantitative results are presented in Figure 4C -H. These data suggested that OGN negatively regulates VEGF-VEGFR2 signalling. 
.5 OGN is associated with VEGFR2 and negatively modulated VEGF-VEGFR2 interactions
To investigate how OGN regulates the VEGFR2 signalling pathway, we performed a co-immunoprecipitation (co-IP) assay between OGN and VEGFR2. We found that IP of OGN pulled down VEGFR2 ( Figure 5A ) and IP of VEGFR2 pulled down OGN ( Figure 5C ) in cultured HUVECs. We also performed co-IP using samples of mouse skeletal muscles and obtained similar findings ( Figure 5B and D) . Moreover, in OGN-deficient ECs from OGN KO mice, exogenous OGN could also interact with VEGFR2 in ECs (Supplementary material online, Figure 6 ). These results strongly suggested a physical association between OGN and VEGFR2. We next examined the effect of VEGF on the OGN-VEGFR2 interaction. A 5-min treatment with VEGF did not change the expression of either OGN or VEGFR2 ( Figure 5F ). However, the association of OGN and VEGFR2 as detected by co-IP was attenuated by VEGF stimulation ( Figure 5E ). Furthermore, we examined the effect of OGN on the interaction between VEGF and VEGFR2. We found that knockdown of OGN did not increase VEGF expression but enhanced the association of VEGF-VEGFR2 with or without VEGF treatment ( Figure 5G and H). These data suggested that by associating with VEGFR2, OGN competed with VEGF to interact with VEGFR2, thus serving as an inhibitory role of VEGF-VEGFR2 signalling.
Inhibition of VEGFR2 abrogated the effects of OGN KO in vivo
To determine the role of VEGFR2 in OGN-mediated effects in vivo, a VEGFR2 inhibitor was used. Mice were injected with the VEGFR2 inhibitor, and blood flow was assessed 14 days after surgery. As shown in Figure 6A , the VEGFR2 inhibitor impeded the perfusion recovery in both OGN WT and KO mice. The perfusion recovery of WT and KO mice after VEGFR2 inhibition was no longer significantly different. The quantitative result is presented in Figure 6C . Similarly, there was no difference of CD31-positive cells in these two groups ( Figure 6B) , and the quantitative result is presented in Figure 6D . These data indicate that the proangiogenic effect of OGN KO was abrogated by the VEGFR2 inhibitor and suggest that VEGFR2 is a key mediator in OGN-regulated angiogenesis.
Discussion
In the present study, we provided novel insight into the role of OGN in ischaemia-induced angiogenesis using both in vitro and in vivo approaches. We found that the loss of OGN is protective against ischaemia through the activation of an angiogenic signalling pathway. Another key discovery 
from the present study is that OGN, as an ECM proteoglycan, associates with the tyrosine kinase receptor VEGFR2 and thus regulates the VEGF-VEGFR2 interaction. We also provided evidence demonstrating that VEGFR2 functions as a key mediator in OGN-mediated regulation of angiogenesis. To our knowledge, this is the first report that OGN participates in angiogenesis, and OGN is a key negative regulator of VEGF-VEGFR2 signalling by binding to VEGFR, a crucial receptor in angiogenesis ( Figure 6E) .
The interaction of the ECM and VEGFR2 has long been a focus in angiogenesis. Harbouring 7 leucine-rich repeats in its structure, OGN belongs to the small leucine-rich proteoglycan (SLRP) family, which is characterized by relatively small protein cores and tandem leucine-rich repeats. In recent years, the importance of the SLRP family in angiogenesis has been reported. [18] [19] [20] For example, decorin, one of the most intensively studied members of the SLRP family, has also been found to interact with VEGFR2 via its core peptides LRR5 and thus attenuates cell proliferation and migration induced by VEGF. 21 Moreover, Thomas Neill et al. also found that decorin has a high binding affinity to VEGFR2 in a region between Ig domains 3-5, which partially overlap with VEGF-A. 22 Interestingly, although both decorin and OGN belongs to the same family and can interact with the same receptor, the amino acid sequence in decorin that binds to VEGFR2 21, 22 is not present in OGN. Therefore, we performed a molecular docking analysis of OGN to VEGFR2 to understand how OGN associates with VEGFR2. As shown in Supplementary material online, Figure 7 , OGN was docked into the binding pocket of the VEGF2. The detailed analysis shows that Tyr196, Glu176, and Glu108 of OGN form hydrogen bonds with residues Glu140, Tyr194, and Tyr190 of VEGF2, respectively, which is the main binding interaction between OGN and VEGF2. This model of molecular simulation supports the direct interaction between OGN and VEGF2 and provides valuable information for further understanding how OGN functions.
The source of OGN detected in limb vasculature is likely contributed by multiple cell types, including ECs, SMCs, and others. We have shown expression of OGN in CD31-positive EC cells by immunostaining ( Figure  1D ) and in cultured HUVECs by RT-PCR, western blotting, and ELISA (Supplementary material online, Figure 5 and Table 1) . We detected OGN in the supernatant of cultured HUVECs (1887 6 569 pg/mL, n ¼ 6 cultures); by comparison, the levels of OGN detected in the supernatants from human vascular smooth muscle cells were higher (4396 and 5470 pg/mL in two independent experiments). However, a few previous studies failed to detect OGN in EC by either in situ hybridization phosphorylation (E) using ImageJ. Two-way ANOVA followed by Bonferroni post test was used to determine significance. *P < 0.05 vs. NC. #P < 0.05 vs. NC at 5 min. @P < 0.05 vs. NC at 15 min. $P < 0.05 vs. NC at 30 min. (F) Bar graph of quantification of VEGFR2 phosphorylation using ImageJ. Two-way ANOVA followed by Bonferroni post test was used to determine significance. *P < 0.05 vs. control at 5 min. #P < 0.05 vs. control at 15 min. @P < 0.05 vs. control at 30 min. Bar graph of quantification of AKT phosphorylation (G), and ERK1/2 phosphorylation (H) using ImageJ. Two-way ANOVA followed by Bonferroni post test was used to determine significance. *P < 0.05 vs. control. #P < 0.05 vs. control at 5 min. @P < 0.05 vs. control at 15 min. $P < 0.05 vs. control at 30 min. OGN, osteoglycin; VEGFR2, vascular endothelial growth factor receptor 2; HUVECs, human umbilical vein endothelial cells; siRNA, small interfering ribonucleic acid; VEGF, vascular endothelial growth factor; NC, negative control. 
or immunostaining. 23, 24 The discrepancy might be due to the different sensitivities of the detection methods used in current study and previous studies from a decade ago. In addition to ECs, we found that SMCs also highly express OGN, which is consistent with previous reports of detecting OGN in the vasculature. 23, 24 Thus, OGN, when localized in proximity with CD31-positive EC cells ( Figure 1D ), might be derived from more than one cell type. Regardless of the source of OGN, we believe that extracellular OGN plays a critical role in regulating VEGF-VEGFR2 signalling in ECs and subsequently modulates the angiogenic process. Inflammation has also been implicated in angiogenesis. 1 We therefore performed immunostaining of CD45 and found no difference between the two groups (Supplementary material online, Figure 2B) . Furthermore, the expression of inflammatory cytokines such as TNF-a, IL-1b, IL-6, and MCP-1 in ischaemic gastrocnemius muscles from KO mice did not significantly differ from those of WT mice (Supplementary material online, Figure 2D -G). In the ex vivo culture model, more resident ECs were sprouting out in OGN-null aortic rings than WT rings, but there was no recruitment of inflammatory cells ( Figure 2D ). These observations suggest that OGN does not regulate the inflammatory response. Arteriogenesis, which is the enlargement of collateral vessels after ischaemia, is also an undeniable factor that influences blood flow recovery. 25 We were uncertain whether enhanced neovascularization could still be observed in KO mice without the participation of arteriogenesis. As the cornea is avascular, an alkali injury-induced corneal neovascularization model was used to rule out the possibility of involvement of collateral circulation. 26, 27 We found that KO mice had more robust angiogenesis with more CD31 after alkali injury (Supplementary material online, Figure 3 ). These data make it reasonable to speculate that the difference in blood flow recoveries may be largely attributable to the function of ECs.
Our study also has some clinical perspectives. The phenomenon of OGN down-regulation in an angiogenic region is also observed in the skeletal muscle of PAD patients (Supplementary material online, Figure  8 ), which is in accordance with the results of our animal experiments. It is known that capillary density is lower in the limbs of PAD patients suffering from chronic and severe ischaemia, and angiogenic regions are actually insufficient and desired in PAD patients in the later stages of disease. 28 Therefore, it is rational to suggest that down-regulating the expression of OGN in PAD patients to induce therapeutic angiogenesis may be a new target for PAD treatment.
In conclusion, our results suggested that the down-regulation of OGN has beneficial effects on endothelial sprouting and that as a proteoglycan of the ECM, OGN modulates the VEGF-VEGFR2 interaction and consequently influences angiogenesis ( Figure 6E) . Thus, OGN may become a novel therapeutic target for ischaemic vascular diseases.
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Supplementary material is available at Cardiovascular Research online.
